|
Market Closed -
Euronext Paris
09:25:00 14/10/2026 pm IST
|
Pre-market 10:41:00 am | |||
| 5.640 EUR | -3.59% |
|
5.603 | -0.66% |
| Market Cap | 5.81Cr 6.46Cr 5.42Cr 4.92Cr 9.23Cr 615.16Cr 9.29Cr 65Cr 25Cr 319.27Cr 24Cr 24Cr 1.03TCr | P/E 2026 * |
-1.68x | P/E 2027 * | -2.52x |
|---|---|---|---|---|---|
| Enterprise Value | -1.59Cr -1.77Cr -1.48Cr -1.34Cr -2.52Cr -168.08Cr -2.54Cr -18Cr -6.94Cr -87Cr -6.63Cr -6.49Cr -280.57Cr | EV / Sales 2026 * |
-3.41x | EV / Sales 2027 * | -1.06x |
| Free-Float |
65.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALSEN | Real-time | |
Börse Stuttgart
| RFM | Delayed | |
|
Tradegate
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Börse Stuttgart
| RFM | Delayed | |
|
Deutsche Boerse AG
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
CBOE
| Real-time |
| 1 day | -3.59% | ||
| 1 week | -13.81% | ||
| Current month | -22.57% | ||
| 1 month | -48.14% | ||
| 3 months | -56.62% | ||
| 6 months | -71.00% | ||
| Current year | -66.53% |
| 1 week | 5.58 |  | 6.18 |
| 1 month | 5.58 | | 10.86 |
| Current year | 5.58 | | 40.4 |
| 1 year | 5.58 | | 40.4 |
| 3 years | 5.58 | | 52 |
| 5 years | 5.58 | | 114.5 |
| 10 years | 5.58 | | 387 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frédéric Chéreau
CEO | Chief Executive Officer | 59 | 01/06/2026 |
Louis Arcudi
DFI | Director of Finance/CFO | 65 | 07/10/2026 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 11/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 09/03/2015 | |
Julien Miara
BRD | Director/Board Member | 43 | - |
Khalil Barrage
CHM | Chairman | 61 | 30/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 06/02/26 | Redmile Biopharma Investments III LP
| Buy | Company | 1,89,28,571 | 6.2956% | |
| 31/01/26 | Sofinnova Partners SAS
| Buy | Company | 1,07,14,285 | 3.5636% | |
| 18/04/24 | Redmile Biopharma Investments III LP
| Buy | Company | 27,81,914 | 1.0091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -3.59% | -13.81% | -68.84% | -80.38% | 6.46Cr | |
| -2.01% | -7.86% | +60.74% | +70.97% | 6.89TCr | |
| +3.84% | -11.02% | +8.59% | +57.43% | 5.19TCr | |
| +3.35% | +1.42% | +11.85% | +40.01% | 4.87TCr | |
| +0.51% | +1.51% | +27.96% | +31.43% | 4.31TCr | |
| +2.70% | -3.66% | +307.41% | +547.01% | 4.15TCr | |
| +0.69% | -3.44% | +9.52% | +96.59% | 4TCr | |
| +0.06% | -2.02% | +11.25% | +43.27% | 3.06TCr | |
| -0.56% | -8.58% | +37.62% | +0.94% | 2.6TCr | |
| -0.39% | -6.92% | -13.60% | -14.40% | 2.23TCr | |
| Average | +0.46% | -5.51% | +39.25% | +79.28% | 3.73TCr | |
| Weighted average by Cap. | +0.98% | -4.28% | +55.11% | +103.86% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 46.63L 51.86L 43.51L 39.44L 74.04L 49Cr 74.5L 5.22Cr 2.04Cr 26Cr 1.95Cr 1.9Cr 82Cr | 1.59Cr 1.77Cr 1.49Cr 1.35Cr 2.53Cr 168.51Cr 2.54Cr 18Cr 6.96Cr 87Cr 6.65Cr 6.5Cr 281.28Cr |
| Net income | -3.6Cr -4Cr -3.36Cr -3.04Cr -5.72Cr -381.04Cr -5.75Cr -40Cr -16Cr -197.76Cr -15Cr -15Cr -636.05Cr | -2.88Cr -3.2Cr -2.69Cr -2.43Cr -4.57Cr -304.69Cr -4.6Cr -32Cr -13Cr -158.14Cr -12Cr -12Cr -508.6Cr |
| Net Debt | -7.4Cr -8.23Cr -6.91Cr -6.26Cr -12Cr -783.24Cr -12Cr -83Cr -32Cr -406.51Cr -31Cr -30Cr -1.31TCr | -7.5Cr -8.34Cr -7Cr -6.34Cr -12Cr -793.83Cr -12Cr -84Cr -33Cr -412Cr -31Cr -31Cr -1.33TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/26/14 | €5.640 | -3.59% | 7,335 |
| 13/26/13 | €5.850 | +0.39% | 8,957 |
| 12/26/12 | €5.827 | -0.39% | 10,112 |
| 09/26/09 | €5.850 | -0.85% | 12,170 |
| 08/26/08 | €5.900 | -9.84% | 14,961 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ALSEN Stock
Select your edition
All financial news and data tailored to specific country editions
